Revitope

Biotechnology ResearchMassachusetts, United States11-50 Employees

Revitope is an early stage biotechnology company focused on developing the next-generation of T cell redirecting biologics. 

Immune-based therapies are redefining how cancer is treated as clinical studies demonstrate unprecedented deep and durable responses in multiple cancers. In particular redirecting T cells to tumors is a successful strategy for immunotherapy of liquid tumors. However, unleashing a potent immune response that is entirely focused on the tumor continues to be elusive.

Revitope is developing a new class of biologic prodrugs we call Programmable Antibody Circuits or PACs that are engineered to focus immune activation to the cancer cell surface while expanding the antigenic targeting space.

Sign up for free to view info

Email Format Employee directory